Data from two Phase III trials in adult and pediatric patients for MM 36 showed statistically significant improvements in atopic dermatitis.- Medimetriks Pharmaceuticals
Related news and insights
Incyte and Maruho Co., Ltd. announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte's selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan.
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving RG 3637 (lebrikizumab) combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75) in the phase III ADhere trial, Eli Lilly has announced at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference.
More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company announced at the American Academy of Dermatology (AAD) Annual Meeting.